Status:

UNKNOWN

Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma

Lead Sponsor:

Medical University of Vienna

Conditions:

Uveal Melanoma

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The purpose of this study is to assess the safety and efficacy of hypofractionated stereotactic LINAC radiotherapy with 10 fractions at 6 Gy per fraction at the 80% isodose for the planning target vol...

Eligibility Criteria

Inclusion

  • The initial height of the melanoma is 7 mm or higher.
  • Juxtapapillary and/or juxtamacular melanomas with a height of 3 mm or higher and if the central tumor distance to the optic disc and/or the macula is 3 mm or less.
  • If other forms of conservative treatment of the melanoma are not possible.

Exclusion

  • Prior/Concomitant Treatment.
  • Extrascleral tumor extension is present.
  • If the presence of neovascular glaucoma is detected before treatment.
  • If metastasis is detected at baseline.
  • Previous participation in any study of investigational drugs within 3 month preceding day 0.
  • Pregnant women are not allowed to participate in the study.

Key Trial Info

Start Date :

March 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

Estimated Enrollment :

155 Patients enrolled

Trial Details

Trial ID

NCT00872391

Start Date

March 1 2009

Last Update

March 31 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Ophthalmology and the Department of Radiotherapy and Radiobiology, Medical University of Vienna

Vienna, Vienna, Austria, 1090

Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma | DecenTrialz